Literature DB >> 24964950

The value of HIV protective epitope research for informed vaccine design against diverse viral pathogens.

Victor G Kramer1, Siddappa N Byrareddy.   

Abstract

The success of vaccine regimens against viral pathogens hinges on the elicitation of protective responses. Hypervariable pathogens such as HIV avoid neutralization by masking protective epitopes with more immunogenic decoys. The identification of protective, conserved epitopes is crucial for future vaccine candidate design. The strategies employed for identification of HIV protective epitopes will also aid towards rational vaccine design for other viral pathogens.

Entities:  

Keywords:  H1N1; HIV; epitope; glycan; vaccine

Mesh：

Substances：

Year:  2014        PMID： 24964950      PMCID： PMC4128321          DOI： 10.1586/14760584.2014.928597

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  25 in total

1.  The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines.

Authors:  Florian Krammer; Rebecca J Cox
Journal:  Expert Rev Vaccines       Date:  2013-10-25       Impact factor: 5.217

Review 2.  Structural basis of immune recognition of influenza virus hemagglutinin.

Authors:  I A Wilson; N J Cox
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

3.  Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery.

Authors:  Michael Mühle; Kerstin Hoffmann; Martin Löchelt; Joachim Denner
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

4.  Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults.

Authors:  P M Mendelman; J Cordova; I Cho
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

5.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

6.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

7.  Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.

Authors:  Marie Pancera; Syed Shahzad-Ul-Hussan; Nicole A Doria-Rose; Jason S McLellan; Robert T Bailer; Kaifan Dai; Sandra Loesgen; Mark K Louder; Ryan P Staupe; Yongping Yang; Baoshan Zhang; Robert Parks; Joshua Eudailey; Krissey E Lloyd; Julie Blinn; S Munir Alam; Barton F Haynes; Mohammed N Amin; Lai-Xi Wang; Dennis R Burton; Wayne C Koff; Gary J Nabel; John R Mascola; Carole A Bewley; Peter D Kwong
Journal:  Nat Struct Mol Biol       Date:  2013-05-26       Impact factor: 15.369

8.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Chaim A Schramm; Jason Gorman; Penny L Moore; Jinal N Bhiman; Brandon J DeKosky; Michael J Ernandes; Ivelin S Georgiev; Helen J Kim; Marie Pancera; Ryan P Staupe; Han R Altae-Tran; Robert T Bailer; Ema T Crooks; Albert Cupo; Aliaksandr Druz; Nigel J Garrett; Kam H Hoi; Rui Kong; Mark K Louder; Nancy S Longo; Krisha McKee; Molati Nonyane; Sijy O'Dell; Ryan S Roark; Rebecca S Rudicell; Stephen D Schmidt; Daniel J Sheward; Cinque Soto; Constantinos Kurt Wibmer; Yongping Yang; Zhenhai Zhang; James C Mullikin; James M Binley; Rogier W Sanders; Ian A Wilson; John P Moore; Andrew B Ward; George Georgiou; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris; Peter D Kwong; Lawrence Shapiro; John R Mascola
Journal:  Nature       Date:  2014-03-02       Impact factor: 49.962

9.  Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors.

Authors:  S Munir Alam; S Moses Dennison; Baptiste Aussedat; Yusuf Vohra; Peter K Park; Alberto Fernández-Tejada; Shelley Stewart; Frederick H Jaeger; Kara Anasti; Julie H Blinn; Thomas B Kepler; Mattia Bonsignori; Hua-Xin Liao; Joseph G Sodroski; Samuel J Danishefsky; Barton F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

Review 10.  Passive immunization as tool to identify protective HIV-1 Env epitopes.

Authors:  Victor G Kramer; Nagadenahalli B Siddappa; Ruth M Ruprecht
Journal:  Curr HIV Res       Date:  2007-11       Impact factor: 1.581
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.